Fig. 3. oFV vectors carrying therapeutic transgenes efficiently propagate in subcutaneous indicator U251-U3-mCherry-U3-Luc tumors and facilitate expression of the transgenes.

Subcutaneous U251-U3-mCherry-U3-luc tumors were injected with five doses of 2 * 10⁶ IU of oFV-TK, oFV-iCasp9 or PBS control every 2 days, 14 days after the first infection the mice were injected intraperitoneally with GCV at 50 mg/kg daily for four five-day cycles, AP20187 at 5mg/kg daily for four days or mock control, A., C. bioluminescence imaging of the tumor bearing mice infected with oFV-TK (A) and oFV-iCasp9 (C). B., D. Quantification of the average radiance for each mouse in the experiment infected with mice infected with oFV-TK (B) and oFV-iCasp9 (D). GCV/AP20187 treatment leads to a decrease in luminescence in the oFV-TK/oFV-iCasp9 infected indicator tumors. Red arrows indicate the time points at which GCV/AP20187 treatment was started/stopped.